| Outcome Measures: |
Primary: PartA: Number of participants with adverse events (AEs) and serious adverse events (SAEs), To assess the safety and tolerability of AZD5004 following single oral doses in healthy participants., From screening (Day -28) to last follow up visit (Day 8)|PartB: Number of participants with adverse events (AEs) and serious adverse events (SAEs), To assess the safety and tolerability of AZD5004 following multiple oral ascending doses in participants with T2DM., From screening (Day -28) to last follow up visit (Day 119 ) | Secondary: PartB: AUC0-4 for glucose, insulin and C-peptide for MMTT, To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD, From Day 1 to Day 105|PartB: Absolute change from baseline to Day 105 in fasting plasma glucose, To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD, From Day 1 to Day 105|PartB: % change from baseline to Day 105 in HOMA-IR, To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD, From Day 1 to Day 105|PartB: The proportion of time in hyperglycaemia /hypoglycaemia over the last 7-day intervals at each dose level in CGM, To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD, From Day 1 to Day 106|PartB: % change from baseline to Day 105 in body weight (kg), To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD, From Day 1 to Day 105|PartB: % change from baseline to Day 105 in waist circumference (cm), To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD, From Day 1 to Day 105|PartA: Area under the Plasma Concentration vs. Time Curve(AUC0-24), To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD, From Day 1 to Day 6|PartA: Area under the Plasma Concentration vs. Time Curve from Zero until the Time of the Last Concentration above the Limit of Quantification(AUC0-tlast), To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD, From Day 1 to Day 6|PartA: Area under the Plasma Concentration vs. Time Curve from Zero to Infinity(AUC0-inf), To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD, From Day 1 to Day 6|PartA: Maximum Observed Plasma Concentration(Cmax), To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD, From Day 1 to Day 6|PartA: Plasma Concentration at 24 Hours Post-Dose(C24h), To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD, From Day 1 to Day 6|PartA: Time of Occurrence of Maximum Plasma Concentration(tmax), To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD, From Day 1 to Day 6|PartA: Lag Time before Observation of Quantifiable Analyte Concentrations in Plasma(tlag), To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD, From Day 1 to Day 6|PartA: Half-Life(t1/2), To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD, From Day 1 to Day 6|PartA: Last measurable Non-Zero Concentration(Clast), To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD, From Day 1 to Day 6|PartA: Last measurable Non-Zero ConcentrationTime to Last Detectable Concentration(tlast), To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD, From Day 1 to Day 6|PartA: Apparent Oral Clearance(CL/F), To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD, From Day 1 to Day 6|PartA: Cumulative Urinary Excretion(Ae), To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD, From Day 1 to Day 6|PartA: Clearance(CLR), To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD, From Day 1 to Day 6|PartB: Area under the Plasma Concentration vs. Time Curve(AUC0-24), To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD, Day 1|PartB: Maximum Observed Plasma Concentration(Cmax), To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD, Day 1, Day 49, Day 63, Day 77, Day91, Day105|PartB: Plasma Concentration at 24 Hours Post-Dose(C24h), To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD, Day 1|PartB: Time of Occurrence of Maximum Plasma Concentration(tmax), To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD, Day 1, Day 49, Day 63, Day 77, Day91, Day105|PartB: Lag Time before Observation of Quantifiable Analyte Concentrations in Plasma(tlag), To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD, Day 1|PartB: Area under the Plasma Concentration vs. Time Curve over the Dosing Interval(AUC0-τ), To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD, Day 49, Day 63, Day 77, Day 91, Day 105|PartB: Observed Concentration at the End of the Dosing Interval(Cτ), To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD, Day 49, Day 63, Day 77, Day 91, Day 105|PartB: Half-Life(t1/2), To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD, Day 49, Day 63, Day 77, Day 91, Day 105|PartB: Apparent Oral Clearance(CL/F), To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD, Day 49, Day 63, Day 77, Day 91, Day 105|PartB: Cumulative Urinary Excretion(Ae), To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD, Day 105|PartB: Clearance(CLR), To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD, Day 105
|
